Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr-Jun;45(2):266-274.
doi: 10.1016/j.htct.2022.08.002. Epub 2022 Sep 20.

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Vania Hungria  1 , Ana Alfonso Piérola  2 , Jayr Schmidt Filho  3 , Edvan Crusoe  4 , Roberto José Pessoa de Magalhães Filho  5 , Angelo Maiolino  6 , Paula Rodríguez-Otero  7
Affiliations

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Vania Hungria et al. Hematol Transfus Cell Ther. 2023 Apr-Jun.

Abstract

Introduction: Chimeric antigen receptor T (CAR-T) cell therapy is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) that is a multi-step process involving various stakeholders. Appropriate education on the practical logistics is therefore paramount to ensure treatment success.

Methods: A group of key opinion leaders met to explore the key elements of setting up and running a CAR-T center in Brazil. For each step in the CAR-T cell therapy process, the experts agreed on basic requirements, gave their key recommendations from practical experience, and considered any remaining unanswered questions.

Results: This paper presents best-practice recommendations and advice on how to overcome common challenges for each step in the CAR-T cell therapy process, with a focus on the current situation in Brazil. Key themes throughout the process are collaboration within the multidisciplinary team and with the referring physician, along with communication and education for patients and their caregivers.

Conclusion: We believe that the expert insights presented in this paper, in particular on optimal patient selection and timing of CAR-T cell therapy, will deepen understanding of the CAR-T process and aid implementation of this novel therapy for patients with RRMM in Brazil.

Keywords: BCMA; Bridging therapy; CAR-T cell therapy; Immunotherapy; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest AAP: Honoraria from lectures: BMS, Janssen, Gilead-Kite, Astellas, Jazz Pharmaceuticals Participation in Advisory Board meetings: BMS, Jazz Pharmaceuticals Consultant: Astellas AM: Honoraria from lectures: BMS, Janssen, Sanofi, Amgen, Takeda Participation in Advisory Board meetings: BMS, Janssen, Sanofi, Takeda, Pfizer Consultant: BMS, Pfizer, Astra Zeneca, Novartis, Janssen EC: Research funding: Janssen JSF: Honoraria from lectures and Advisory Boards: Janssen, Novartis, Kite/Gilead, BMS, Abbvie, Amgen. RM: Honoraria for lectures and boards: Janssen, Sanofi, Takeda, Amgen, BMS PRO: Honoraria from lectures: BMS, Janssen, Sanofi, GSK, Amgen, Regeneron, Takeda Participation in Advisory Board meetings: BMS, Janssen, Sanofi, Kite Pharma, Abbvie, Oncopeptides, Takeda, Pfizer, GSK Consultant: BMS, Pfizer VH: Honoraria from lectures: Amgen, BMS, GSK, Janssen, Sanofi, Takeda Participation in Advisory Board meetings: BMS, Janssen, Pfizer, Sanofi

Figures

Figure 1
Figure 1
Steps associated with the practical implementation of CAR-T cell therapy. *Including adverse event monitoring.
See this image and copyright information in PMC

References

    1. Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and safety of CAR-T therapy for relapse or tefractory multiple myeloma: A systematic review and meta-analysis. Int J Med Sci. 2021;18(8):1786–1797. - PMC - PubMed
    1. Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84. - PMC - PubMed
    1. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7. - PubMed
    1. CARVYKTI™ (ciltacabtagene autoleucel) suspension for intravenous infusion. Highlights of prescribing information 2022.
    1. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) Ann Oncol. 2021;33(3):259–275. - PubMed